EVOK Profile
Evoke Pharma, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing novel treatments for gastroenterological disorders. The company's primary focus is on addressing unmet needs within the gastrointestinal (GI) space through innovative drug delivery systems and targeted therapies. By concentrating on this specialized area, Evoke aims to offer effective solutions for managing a range of digestive and gastrointestinal conditions.
The company’s lead product is Gimoti, a metoclopramide nasal spray designed to treat symptoms associated with acute and recurrent diabetic gastroparesis, particularly in female patients. This product has successfully completed Phase 3 clinical trials, showcasing its potential to offer significant benefits for individuals suffering from this debilitating condition. Gastroparesis, characterized by delayed stomach emptying and associated symptoms such as nausea and vomiting, represents a challenging area in GI medicine, making Gimoti a potentially transformative treatment option.
Evoke Pharma's commercial strategy involves targeting key healthcare providers who are integral to managing gastroenterological disorders. The company markets its products to a broad range of specialists, including gastroenterologists, internal medicine physicians, and primary care doctors. By engaging with these healthcare professionals, Evoke aims to ensure that its innovative therapies reach patients who would benefit the most, thereby improving treatment outcomes and patient quality of life.
Established in 2007 and headquartered in Solana Beach, California, Evoke Pharma is positioned at the forefront of gastrointestinal therapeutics. The company's commitment to developing cutting-edge treatments and its focus on specialized drug delivery systems reflect its dedication to advancing care in the GI field. By leveraging its expertise and focusing on high-impact areas within gastroenterology, Evoke Pharma seeks to address critical medical needs and enhance therapeutic options for patients with complex gastrointestinal disorders.
|
